Inhibrx, Inc. (NASDAQ: INBX)


Engel Law PLLC is investigating whether fair value to Inhibrx, Inc. (NASDAQ: INBX) shareholders will result from the proposed acquisition of Inhibrx by Sanofi (Nasdaq: SNY) for (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone and (iii) one SEC-registered, publicly listed, share of New Inhibrx per every four shares of Inhibrx common stock held.

The Firm’s investigation concerns:

(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Inhibrx, Inc.

MM slash DD slash YYYY